Prophylactic ranitidine treatment in critically ill children – a population pharmacokinetic study. (8th April 2013)
- Record Type:
- Journal Article
- Title:
- Prophylactic ranitidine treatment in critically ill children – a population pharmacokinetic study. (8th April 2013)
- Main Title:
- Prophylactic ranitidine treatment in critically ill children – a population pharmacokinetic study
- Authors:
- Hawwa, Ahmed F.
Westwood, Paul M.
Collier, Paul S.
Millership, Jeffrey S.
Yakkundi, Shirish
Thurley, Gillian
Shields, Mike D.
Nunn, Anthony J.
Halliday, Henry L.
McElnay, James C. - Abstract:
- <abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bcp4473-sec-0001" sec-type="section"> <title>Aims</title> <p>To characterize the population pharmacokinetics of ranitidine in critically ill children and to determine the influence of various clinical and demographic factors on its disposition.</p> </sec> <sec id="bcp4473-sec-0002" sec-type="section"> <title>Methods</title> <p>Data were collected prospectively from 78 paediatric patients (<italic>n</italic> = 248 plasma samples) who received oral or intravenous ranitidine for prophylaxis against stress ulcers, gastrointestinal bleeding or the treatment of gastro‐oesophageal reflux. Plasma samples were analysed using high‐performance liquid chromatography, and the data were subjected to population pharmacokinetic analysis using nonlinear mixed‐effects modelling.</p> </sec> <sec id="bcp4473-sec-0003" sec-type="section"> <title>Results</title> <p>A one‐compartment model best described the plasma concentration profile, with an exponential structure for interindividual errors and a proportional structure for intra‐individual error. After backward stepwise elimination, the final model showed a significant decrease in objective function value (−12.618; <italic>P</italic> &lt; 0.001) compared with the weight‐corrected base model. Final parameter estimates for the population were 32.1 l h<sup>−1</sup> for total clearance and 285 l for volume of distribution, both allometrically modelled for<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bcp4473-sec-0001" sec-type="section"> <title>Aims</title> <p>To characterize the population pharmacokinetics of ranitidine in critically ill children and to determine the influence of various clinical and demographic factors on its disposition.</p> </sec> <sec id="bcp4473-sec-0002" sec-type="section"> <title>Methods</title> <p>Data were collected prospectively from 78 paediatric patients (<italic>n</italic> = 248 plasma samples) who received oral or intravenous ranitidine for prophylaxis against stress ulcers, gastrointestinal bleeding or the treatment of gastro‐oesophageal reflux. Plasma samples were analysed using high‐performance liquid chromatography, and the data were subjected to population pharmacokinetic analysis using nonlinear mixed‐effects modelling.</p> </sec> <sec id="bcp4473-sec-0003" sec-type="section"> <title>Results</title> <p>A one‐compartment model best described the plasma concentration profile, with an exponential structure for interindividual errors and a proportional structure for intra‐individual error. After backward stepwise elimination, the final model showed a significant decrease in objective function value (−12.618; <italic>P</italic> &lt; 0.001) compared with the weight‐corrected base model. Final parameter estimates for the population were 32.1 l h<sup>−1</sup> for total clearance and 285 l for volume of distribution, both allometrically modelled for a 70 kg adult. Final estimates for absorption rate constant and bioavailability were 1.31 h<sup>−1</sup> and 27.5%, respectively. No significant relationship was found between age and weight‐corrected ranitidine pharmacokinetic parameters in the final model, with the covariate for cardiac failure or surgery being shown to reduce clearance significantly by a factor of 0.46.</p> </sec> <sec id="bcp4473-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Currently, ranitidine dose recommendations are based on children's weights. However, our findings suggest that a dosing scheme that takes into consideration both weight and cardiac failure/surgery would be more appropriate in order to avoid administration of higher or more frequent doses than necessary.</p> </sec> </abstract> … (more)
- Is Part Of:
- British journal of clinical pharmacology. Volume 75:Number 5(2013:May)
- Journal:
- British journal of clinical pharmacology
- Issue:
- Volume 75:Number 5(2013:May)
- Issue Display:
- Volume 75, Issue 5 (2013)
- Year:
- 2013
- Volume:
- 75
- Issue:
- 5
- Issue Sort Value:
- 2013-0075-0005-0000
- Page Start:
- 1265
- Page End:
- 1276
- Publication Date:
- 2013-04-08
- Subjects:
- Pharmacology -- Periodicals
Drugs -- Periodicals
615.1 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2125 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/j.1365-2125.2012.04473.x ↗
- Languages:
- English
- ISSNs:
- 0306-5251
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2307.180000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 3148.xml